Life-changing Sickle Cell Drug: Everything you need to know

Thousands of lives across England are set to change with the approval of a life-changing sickle cell drug, Voxeletor. Following a recommendation from the National Institute for Health and Care Excellence (NICE), the NHS will soon provide this daily tablet to eligible patients. About 17,000 people live with sickle cell disease in England, and roughly 4,000 will qualify for this new treatment.

What Is Sickle Cell Disorder?

Sickle cell disorder causes red blood cells to take on a “sickle” shape. These cells break down early and cannot carry oxygen effectively. This leads to chronic anemia and severe pain episodes called crises. These crises often require hospital care and can be life-threatening.

People with sickle cell may also face strokes, fatigue, delayed growth, infections, and organ damage. Voxeletor works by helping hemoglobin in red blood cells hold more oxygen. It also prevents these cells from deforming into the sickle shape.

---

Patient Experiences: How Voxeletor Is Making a Difference

Hazel Attuta, who has taken Voxeletor for two years, shared her story with Sky News. She explained how chronic pain forced her to leave her finance job. Hazel said the drug improved her energy levels dramatically. “Before, exhaustion from sickle cell limited my daily life and work,” she said. “Since starting Voxeletor, my energy has soared. It changed my physical and mental well-being.” Hazel’s experience reflects the hope this drug offers many patients.

https://www.england.nhs.uk/2024/05/nhs-rolls-out-life-changing-treatment-for-thousands-with-sickle-cell-disease

Community and Charity Support

The approval has sparked celebrations among charities and organizations supporting sickle cell patients. Charles Kwaku-Odoi, CEO of the Caribbean and African Health Network (CAHN), expressed strong support.

He said, “This treatment offers hope for a better quality of life for those with this debilitating condition. We continue to advocate for underserved communities.”

Similarly, John James, CEO of the Sickle Cell Society, described NICE’s decision as “a deeply life-changing and celebrated moment” for patients. These endorsements highlight the broad impact this drug can have.

What’s Next for Patients?

The NHS will begin rolling out Voxeletor soon, ensuring those eligible receive this groundbreaking treatment. This marks a critical step toward improving lives affected by sickle cell disease.

Thank you for reading, click the link below to read more of our Health Articles:

https://insidesuccessmagazine.com/category/health